No Data
No Data
EU to Require Additional Cancer Risk Labeling on CAR T Therapies
Bristol Myers Gets FDA Approval for Autyro for NTRK-positive Cancers
Express News | Bristol Myers Squibb Says FDA Granted Accelerated Approval To Augtyro (Repotrectinib) For Patients With NTRK-Positive Locally Advanced Or Metastatic Solid Tumors
Express News | U.S. Food and Drug Administration Approves Augtyro™ (Repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (Tki), for the Treatment of Patients With Ntrk-Positive Locally Advanced or Metastatic Solid Tumors
Express News | FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With Ntrk Gene Fusion-Positive Solid Tumors
Express News | Bristol-Myers Receives FDA Accelerated Approval For Repotrectinib
No Data